After the US slashed global aid, the South African government stated that only 17% of its HIV spending relied on US funding. But some experts argue that US health initiatives had more bang for buck ...

More than half of people living with HIV in Kenya have delayed starting treatment because they fear their family members will discover their status. This is according to people living with HIV (PLHIV) ...

Malawians must brace for more tough times following the United Sates of America’s (USA) decision to terminate contracts worth ...

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...

In the general population, frailty is an aging-related risk factor for poor outcomes; individuals experiencing frailty face ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

Disparities in HIV diagnosis rates were observed between Black and White individuals in the US from 2017 to 2021.